Atopic dermatitis (AD) is a chronic inflammatory skin disease where >90% of AD patients exhibit Staphylococcus aureus (SA) colonization of their lesional skin. The density of SA colonization has been correlated with both severity of AD lesions and the degree of cutaneous inflammation. A filaggrin-defect atopic dermatitis mouse model (FLG ft/ft mice) has been used previously to correlate the depth of SA skin penetration with upregulation of IL-4, IL-13 and other cytokines. Using this model where mice are first sensitized by ovalbumin and then exposed to 1 x 10 6 colony forming units (CFU) SA, a pilot study was conducted to identify the time course of peak cytokines levels (48 hrs) after cutaneous infection with SA and determine the optimal, treatment window (initiate dosing at 24 hrs). In a second study, animals were treated topically after the 24 hr SA incubation period, and again 8 hrs later, with vehicle or 6% SB414, a cream that releases nitric oxide. At 48 hrs, mice were euthanized and biopsied for SA counts and tissue cytokines levels in all treatment groups (IL-13, IL-4, TSLP, IFNg, IL-17a). Upregulation of individual cytokines in the untreated group ranged from 3 to 18-fold. All cytokine levels in the SB414-treated group, except IL-17a, were statistically indistinguishable from the uninfected, baseline tissue cytokine values. IL-4 was reduced by 87% and IL-13 by 76% compared to placebo treated mice. TSLP, an initiator of the atopic response and a sensitive marker of chemical irritation, was not elevated in SB414-treated infected or uninfected mice, demonstrating the local tolerability of the nitric oxide releasing cream. SA levels in the skin of SB414 treated mice were decreased to 0.5 x 10 5 CFUs, representing a >90% reduction over untreated and vehicle treated mice. Importantly, the anti-staph effects of SB414 were not driven by increased IFN-g tissue cytokine levels. Collectively, these data demonstrate the ability of topically applied 6% SB414 to reduce key Th2 cytokines like IL-4 and IL-13, and to reduce SA burden in an atopic dermatitis mouse model.
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Two rat models of psoriasis for drug development B James and Z Weiyu MD Biosciences, Oakdale, MN Psoriasis is the most common chronic autoimmune skin condition, impacting roughly 125 million people worldwide. The pathogenesis is not wholly understood, though an assumed complex interplay between environmental factors, immune dysregulation and genetic susceptibility. Data suggests that an environmental/pathogenic insult to the skin precipitates the activation of immune cells in the skin leading to a dysregulated pro-inflammatory response. This response triggers secretion of IL-12 and IL-23, causing migration and differentiation of Th17 and Th1 cells. These cells release cytokines such as IL-22 and IL-17A/F driving proliferation of keratinocytes and epithelial cells. It has become increasingly important to model this disease, in immune competent animals such as rats. To this end, MD Biosciences has optimized two psoriasis models in the rat. IMQ mimics a pathogenic insult to the skin, eliciting a robust Th17 immune response leading to plaque formation. IMQ is applied to the shaved backs and ears of naïve rats, and disease progression and skin thickening is monitored. Diseased animals exhibit erythema and plaque formation shortly after the start of the study and progress through termination accompanied by increased biomarkers, IL-22, IL17A and IL-17F. IL-23 is the main pathogenic cytokine in the initiation of psoriasis disease progression and has become a lead target for the clinical treatment. Exogenous IL-23 can be delivered directly to the dermis of rats to induce a downstream cascade of inflammatory biomarker upregulation, erythema and epidermal hyperplasia, similar to what is seen in human psoriatic plaques. The IMQ-and IL-23-induced psoriasis models are robust pre-clinical models to help develop therapeutics, as both models mimic specific disease pathologies. These models can be used to assess efficacy of candidate drugs for pathogenic pathway targeting such as Th17 and IL-23/IL-17. The versatility of the models and the benefits of the rat as a host organism make these models ideal for pre-clinical drug development for psoriasis or other Th17/IL-17 dependent diseases.
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Evaluation of a novel therapy and identification of uncertainties critical to efficacy and competitive differentiation in a Psoriasis PhysioPDÔ Platform M Weis 1 , K Kudrycki 1 , R Baillie 1 , M Reed 1 , A Jauhan 2 , A Dari 2 , S Wachten 2 , M Froehlich 2 , W Prange 2 , R Bursi 2 and P Wabnitz 2 1 Rosa and Co. LLC, San Carlos, CA and 2 Grünenthal GmbH, Aachen, Nordrhein-Westfalen, Germany Quantitative systems pharmacology (QSP) is a novel approach to gain insights into the pathophysiology of a disease, optimize the efficacy of therapies and reduce the risk for new drug development. Together with Grü nenthal, Rosa developed a QSP model, a Psoriasis PhysioPD Research Platform to mechanistically represent the physiology of a single chronic psoriatic plaque (including keratinocytes, immune cells, cytokines and chemokines and their regulation), drug PK and clinical outcomes (e.g., PASI score). The Platform was qualified against standard of care (SOC) therapies. Simulations provided insights into the therapeutic potential and efficacy of novel small molecule enzyme-specific inhibitors. Sensitivity analysis identified pathways critical for plaque healing. Best-and worst-case scenarios and the impact of target-related uncertainties were evaluated in a cohort of Virtual Patients. Research in the Platform identified uncertainties related to target expression in immune and skin cells, and to drug distribution and availability in the skin. Treatment simulation helped to define the specific conditions under which the novel therapeutic approach would be superior to SOC treatments and to identify in vivo experiments for reducing risk throughout the process of drug development. The in silico research and analysis revealed key conditions under which the novel treatment would offer superior efficacy compared to SOC and identified experiments to confirm these conditions in vivo. The developed Platform is a viable tool for evaluating earlystage drug candidates and reducing the risk for late-stage development. Skin cancer is the most common type of cancer worldwide. Both prevention and protection against skin cancer is a global issue, and an advanced therapy with convenient accessibility and low side effects would be in high demand. In an effort to discover anticancer agents, we identified a novel tubulin inhibitor STK899704, which structure is distinct from other microtubule-binding agents such as colchicine, vinca alkaloids, and taxanes. STK899704 inhibited microtubule polymerization leading to the cell cycle arrest at mitosis, and repressed the proliferation of cancer cell lines from various origins. Moreover, our preclinical evaluation of the novel compound STK899704 revealed both the prevention and regression of tumors using an in vivo skin carcinogenesis model. Interestingly, almost 80% of the tumors treated with STK899704 were regressed with tumor size reduced to one fifth of the initial tumor volume. The efficacy of STK899704 was two times higher than that of 5-fluorouracil, a widely used skin cancer therapeutic. Our results demonstrate the potential of STK899704 to be a promising anticancer chemotherapeutic and an alternative candidate for existing therapies, particularly for the treatment of skin cancer.
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SNA-125, a novel selective kinase inhibitor, improves clinical symptoms in a mouse model of psoriasis L Bertarione, P Lizzul and S Traversa Sienna Biopharmaceuticals, Westlake Village, CA The efficacy of SNA-125, a first-in-class topical selective kinase inhibitor (including JAK3/ TrkA) with low systemic exposure, was evaluated in the imiquimod (IMQ)-induced mouse model of psoriasis (PSO). IMQ 5% cream (AldaraÔ) was applied once daily for 10 days on ears and shaved backs to induce PSO. SNA-125 (5% or 10%) or vehicle (25% transcutol P; 75% propylene glycol) was applied twice daily to ears and backs (2 and 8 hrs post-IMQ) for 10 days, while the positive control was applied once daily (clobetasol 0.05%; 2 hrs post-IMQ). The PSO clinical score (sum of component erythema [0] [1] [2] [3] [4] , plaque [0-5], and punctate redness/scabbing [0-3] scores) was assessed daily. Ear thickness was measured on days 0, 4, 6, 8, and 10. On day 4, PSO-associated cytokine levels were measured on ear punch biopsies for 10% SNA-125. On day 10, spleen weight was measured. Both doses of SNA-125 resulted in significantly greater improvement in PSO clinical score relative to vehicle ([5%]: p<0.01 for days 5, 8, 10 and p<0.05 for day 9; [10%]: p<0.01 for days 4-5, 8-10). Specifically, SNA-125 demonstrated greater improvement in erythema score ([5%]: p<0.01 on days 8-10; [10%]: p<0.01 on days 8-10 and p<0.05 on day 5), plaque score ([both doses]: p<0.01 on days 4-5, 8), and punctate redness/scabbing score ([10%]: p<0.01 on days 9-10). Day 4 ear cytokine levels were similar between 10% SNA-125 and vehicle, though a significant reduction in TNF-a was noted with SNA-125 relative to vehicle (mean AE SEM: 3.63 AE 0.63 vs 8.72 AE 1.02 pg/mg, respectively; p<0.01). Both doses of SNA-125 reduced ear thickness relative to the IMQ-only group, though the effect was not greater than vehicle. On day 10, splenic weight with both doses of SNA-125 was similar to vehicle, which was expected given the low systemic exposure of SNA-125 due to Topical by DesignÔ technology. In summary, these data show that SNA-125 improves clinical features of a well-accepted mouse model of PSO. These findings will be confirmed and extended in ongoing proof-of-concept studies in humans.
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Applying a novel computational drug-repurposing system to psoriasis Q Wang 1 , N Ward 2 , T McCormick 3 , K Cooper 3 and R Xu 4 1 ThinTek LLC, Cleveland, OH, 2 Department of Dermatology, Case Western Reserve University, Cleveland, OH, 3 Dermatology, Case Western Reserve University, Cleveland, OH and 4 Population and Quantitative Health Sciences, CWRU, Cleveland, OH We have recently developed a novel computational drug discovery system (DrugPredict) that simultaneously performs in silico target-based and phenotypic screening on half a million compounds. We have previously applied DrugPredict to identify repurposed candidate drugs for ovarian cancer and experimentally validated that a commonly prescribed pain medication can be used to kill ovarian cancer cells. In the current study, we retargeted DrugPredict to identify repurposed drug candidates for the dermatologic condition psoriasis. Using 67 psoriasis-associated genes identified by Genome Wide Association Studies as the input, the algorithm screened a total of 441,773 chemicals and ranked these chemicals based on their genetic and phenotypic relevance to psoriasis. We then tested the algorithm using 42 FDAapproved psoriasis drugs and showed that DrugPredict ranked these known drugs quite highly. The mean ranking of these known drugs among the list of 441,773 chemicals was in the top 12.67%, their median ranking was in the top 7.84%, with a P value of 2.2494E-11. Among the top ranked chemicals identified by our algorithm, many are previously FDAapproved drugs used to treat diseases other than psoriasis. Therefore, these drugs represent potentially repurposable drug candidates for psoriasis treatment. In summary, we retargeted a novel and experimentally validated drug discovery system (DrugPredict) to identify candidate drugs that may be repurposed for treating psoriasis. We showed that DrugPredict is highly effective in identifying known psoriasis drugs. The top ranked repurposable candidate drugs warrant further experimental validation.
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